ArticleJournal of clinical microbiology2002
Comparative performance of herpes simplex virus type 1-specific serologic assays from MRL and Meridian Diagnostics.
Article in Journal of clinical microbiology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Childhood life events, immune activation and the development of mood and anxiety disorders: the TRAILS study.Translational psychiatry · 2017Article
- Article
- Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012.PloS one · 2015Article
- Light microscopy, culture, molecular, and serologic methods for detection of herpes simplex virus.Journal of clinical microbiology · 2014Review
- Comparative performance of a novel herpes simplex virus type 2-specific enzyme-linked immunosorbent assay using a targeted chain oligopeptide, peptide 55.Clinical and vaccine immunology : CVI · 2009Article
- Adolescent Sexually Transmitted Diseases: Recent Developments.Current infectious disease reports · 2004Article
- Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25-74 in 1992-93: a population-based study.BMC infectious diseases · 2004Article
- Longitudinal reliability of focus glycoprotein G-based type-specific enzyme immunoassays for detection of herpes simplex virus types 1 and 2 in women.Journal of clinical microbiology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two companies, MRL and Meridian Diagnostics, have developed Food and Drug Administration-approved herpes simplex virus type 1 type-specific enzyme immunoassays. The sensitivity, specificity, and overall testing efficiency of these assays were 98.2, 93.8, and 96.6% for MRL and 98.8, 99.0, and 98.1% for Meridian, making both of these kits suitable for use in the clinical lab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.